Eton Pharmaceuticals (ETON) EBIAT (2019 - 2025)
Eton Pharmaceuticals' EBIAT history spans 7 years, with the latest figure at -$1.9 million for Q3 2025.
- For Q3 2025, EBIAT fell 407.34% year-over-year to -$1.9 million; the TTM value through Sep 2025 reached -$6.7 million, down 21.91%, while the annual FY2024 figure was -$3.8 million, 308.44% down from the prior year.
- EBIAT for Q3 2025 was -$1.9 million at Eton Pharmaceuticals, up from -$2.6 million in the prior quarter.
- Across five years, EBIAT topped out at $5.1 million in Q1 2021 and bottomed at -$9.0 million in Q4 2022.
- The 5-year median for EBIAT is -$1.9 million (2025), against an average of -$1.7 million.
- The largest annual shift saw EBIAT crashed 968.24% in 2022 before it surged 392.62% in 2023.
- A 5-year view of EBIAT shows it stood at $1.0 million in 2021, then plummeted by 968.24% to -$9.0 million in 2022, then surged by 74.99% to -$2.3 million in 2023, then skyrocketed by 73.49% to -$598000.0 in 2024, then crashed by 222.24% to -$1.9 million in 2025.
- Per Business Quant, the three most recent readings for ETON's EBIAT are -$1.9 million (Q3 2025), -$2.6 million (Q2 2025), and -$1.6 million (Q1 2025).